Status:
COMPLETED
Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery
Lead Sponsor:
Dr. Promise Tamunoipiriala Jaja
Conditions:
Surgical Site Infection
Antibiotics Prophylaxis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
BACKGROUND: Surgical site infection (SSI) is potentially catastrophic in neurosurgical procedures, causing poor in-hospital outcomes in more than half of those affected and significantly increased len...
Detailed Description
BACKGROUND Surgical Site Infection (SSI) is the most common health care-associated infection in hospitalized patients, accounting for 31% of all infections globally. The prevalence of SSI is determin...
Eligibility Criteria
Inclusion
- All patients scheduled for clean and clean-contaminated neurosurgical procedures that consent to participating in the study.
Exclusion
- Patients with contaminated and dirty wounds e.g. grossly contaminated open depressed skull fracture, cranial endonasal surgeries and so on.
- Patients who has had systemic antibiotic therapy within 7 days before surgery.
- Patients with diabetes mellitus.
- Patients with implants (they will need longer follow up).
- Allergy to cephalosporins
- Infectious disease such as brain abscess, subdural empyema, osteitis and scalp infection
Key Trial Info
Start Date :
December 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 5 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT05398081
Start Date
December 1 2021
End Date
March 5 2022
Last Update
May 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University College Hospital
Ibadan, Oyo State, Nigeria, 5116